newsfilter
← Latest News
GlobeNewswire·

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed – -